391:1235-1248 (2010) Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM
injections of vehicle or L2-Cmu (20 mg/kg) once per week and were monitored for interim survival to 24 mo of age ( n = 2438 per group) and sacrificed for blood, tissue, and histopathologic analysis
(10 g or 10 ng/kg/day), topical (1.0 g in cream), or per-oral (0.16 g/mL in drinking water) over 90 days and described directional improvements across biomechanical, functional, macroscopic, and histological endpoints, though specific effect sizes and p-values are not reported in the abstract
While regulation of iron metabolism-related proteins or the use of iron chelators can reduce intracellular labile Fe 2+ levels and inhibit ferroptosis, current chelators lack tissue and cellular specificity and may interfere with neurophysiological functions, thereby limiting their clinical applicability